Cognoa, one of the founding partners of the DTx series of summits, has announced FDA breakthrough designations for its lead products.  This is awesome news for Cognoa and another great step for Digital Therapeutics.

Brent Vaughan, CEO writes:

“We believe AI-based precision health can empower parents and their paediatricians to act on early concerns that are highly predictive of developmental delays, like autism, with potentially life-changing results for children and their families. We are thankful that the FDA recognizes the critical need for innovative solutions to help address these challenges. We look forward to working closely with them to further our clinical studies and support our development.”

You can read the full release here.

Brent Vaughan, CEO and Sharief Taraman are members of the 50+ speaker faculty at the flagship DTx West Summit taking place this February in San Mateo, CA.  You can see the full agenda and ticket options here.